Citadel, D.E. Shaw In Conv. Bond Settlement With Indian Pharmaceutical

Mar 11 2010 | 3:08pm ET

A pair of U.S. alternative investments giants has settled a legal battle with an Indian pharmaceutical company over its default on convertible bonds.

Venus Remedies said it has struck a deal with Citadel Investment Group and D.E. Shaw Group. The two firms had sued the company last year after Venus failed to redeem some US$12 million in foreign currency convertible bonds last summer. The pharma blamed the global economic crisis for its decision not to redeem the bonds.

Under the settlement—reached under pressure from the Indian courts—Citadel and D.E. Shaw have agreed to withdraw their winding-up petition, a Venus official told the Press Trust of India. The company will pay the two firms US$7 million within the next 18 months, with the other US$5 million coming over the next five years.

Citadel and D.E. Shaw will also get to keep their investments in Venus.


In Depth

Q&A: Sancus Capital And The Disruption Of The CLO Market

Oct 5 2017 | 6:28pm ET

Traditional collateralized loan obligation (CLO) funds in the U.S. market can offer...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Finding Success as Alternatives Converge

Oct 9 2017 | 4:00pm ET

Rising interest among institutional investors over the past several years has led...

 

From the current issue of